Chronic subdural hematoma (CSDH), a disorder that mainly affects the elderly, is predicted to be the most common cranial neurosurgical disease in America by 2030. Although most patients fare better after surgery, there is still a recurrence ranging from 2.5 to 33%, and the 1-year mortality rate of elderly CSDH patients is 32%. Therefore, delineating the pathophysiologic mechanisms to further improve the outcome of non-surgical treatment is beneficial to CSDH patients, especially those elderly patients who are unable to tolerate surgery. Additionally, complications associated with the recurrence of CSDH are increasing with the widespread use of antithrombotic agents such as anticoagulants and antiplatelet agents. Clearly, the optimum perioperative strategy needs to be further studied.
This Research Topic aims to advance our understanding of the pathogenesis of CSDH and to improve the treatment and prognosis of CSDH patients. Dexamethasone, Atorvastatin, Tranexamic Acid, Angiotensin-Converting Enzyme Inhibitors and other local drugs have been studied for the non-surgical treatment for CSDH. Only Atorvastatin therapy has been proved to be effective in the RCT trial. Further clinical trials are necessary to test whether other drugs are also effective. Whether Atorvastatin therapy can prevent the recurrence and the mechanisms of CSDH needs to be further addressed through clinical and animal studies.
Specifically, we welcome original research articles and reviews that focus on the etiology, pathogenesis, epidemiology and treatment of CSDH including papers on:
• Studies on animal models to examine the pathogenesis of CSDH
• The etiology and epidemiology of CSDH
• The appropriate use of anticoagulant and anti-platelet drugs during the perioperative period
• Conservative treatment of CSDH
• Surgical treatment of CSDH
• The mechanism of Atorvastatin therapy
Chronic subdural hematoma (CSDH), a disorder that mainly affects the elderly, is predicted to be the most common cranial neurosurgical disease in America by 2030. Although most patients fare better after surgery, there is still a recurrence ranging from 2.5 to 33%, and the 1-year mortality rate of elderly CSDH patients is 32%. Therefore, delineating the pathophysiologic mechanisms to further improve the outcome of non-surgical treatment is beneficial to CSDH patients, especially those elderly patients who are unable to tolerate surgery. Additionally, complications associated with the recurrence of CSDH are increasing with the widespread use of antithrombotic agents such as anticoagulants and antiplatelet agents. Clearly, the optimum perioperative strategy needs to be further studied.
This Research Topic aims to advance our understanding of the pathogenesis of CSDH and to improve the treatment and prognosis of CSDH patients. Dexamethasone, Atorvastatin, Tranexamic Acid, Angiotensin-Converting Enzyme Inhibitors and other local drugs have been studied for the non-surgical treatment for CSDH. Only Atorvastatin therapy has been proved to be effective in the RCT trial. Further clinical trials are necessary to test whether other drugs are also effective. Whether Atorvastatin therapy can prevent the recurrence and the mechanisms of CSDH needs to be further addressed through clinical and animal studies.
Specifically, we welcome original research articles and reviews that focus on the etiology, pathogenesis, epidemiology and treatment of CSDH including papers on:
• Studies on animal models to examine the pathogenesis of CSDH
• The etiology and epidemiology of CSDH
• The appropriate use of anticoagulant and anti-platelet drugs during the perioperative period
• Conservative treatment of CSDH
• Surgical treatment of CSDH
• The mechanism of Atorvastatin therapy
